

Laparoscopy: A Procedure no less than Laparotomy for Lymph Node Dissection in Total Gastrectomy for Gastric Carcinoma

T Anil Kumar, Manoj Gowda, Manash Ranjan Sahoo

ABSTRACT

Aim: To show that laparoscopic lymph node dissection and harvesting is equal to laparotomic lymph node dissection in patients undergoing total gastrectomy for gastric carcinoma.

Materials and methods: Retrospective data was collected from 36 patients who underwent total gastrectomy for carcinoma stomach. Fifteen patients underwent open total gastrectomy (OG) and other 21 laparoscopic assisted total gastrectomy (LAG) over a period of 4 years from March 2009 to June 2012. In the laparoscopic group, dissection of lymph nodes and division of ligaments and omentum was done laparoscopically using harmonic scalpel. Both groups were compared for operative blood loss, operative time, blood transfusion, morbidity, mortality, the number of harvested lymph nodes (HLNs) with emphasis on harvested lymph nodes.

Results: There were no significant differences in morbidity or mortality in both groups. Tumor free margins were obtained in all cases. Compared with OG group, the LAG group had significantly less blood loss, but a longer operation time. The mean harvested lymph nodes (HLN's) is 24.7 in LAG group as compared 23.3 in OG group.

Conclusion: Laparoscopic dissection and harvested lymph nodes is equivalent to OG with no other significant differences except for decreased blood loss and increased operative time. Thus, this procedure can achieve the same result as OG.

Keywords: Open gastrectomy, Laparoscopic-assisted gastrectomy, Gastric cancer, Harvested lymph nodes.

How to cite this article: Kumar TA, Gowda M, Sahoo MR. Laparoscopy: A Procedure no less than Laparotomy for Lymph Node Dissection in Total Gastrectomy for Gastric Carcinoma. *World J Lap Surg* 2013;6(3):111-115.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

While laparoscopic approaches are used for many abdominal procedures and allow for faster recovery of bowel function, better immunologic response and overall accelerated recovery for the patient, the use of laparoscopy for cancer surgery is still a matter of debate. For patients with cancer, questions remain about the immunologic implications of laparoscopic surgery, the adequacy and standardization of laparoscopic techniques, the risk for disease recurrence, and the impact on survival. The safety and efficacy of laparoscopic surgery for colorectal cancer has certainly been

established, but the same rigorous approach to other cancers has yet to be reported. Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide.^{1,2} In the Far East countries such as China,³ Korea⁴ and Japan,⁵ gastric cancer is the most prevalent malignancy, and the leading cause of cancer-related deaths. Since the first report of laparoscopic gastrectomy in 1992,⁶ laparoscopy-assisted gastrectomy (LAG) has been carried out not only in distal gastrectomy, but also in proximal gastrectomy and total gastrectomy.⁷⁻⁹ Several randomized control trials (RCTs) have shown that LAG can be performed in early gastric cancer (EGC).¹⁰⁻¹⁵ Radical surgical resection of the stomach and regional lymph nodes dissection is still the mainstream of the treatment of AGC. However, LAG for the treatment of advanced gastric cancer (AGC) has remained controversial, mainly due to a lack of evidence from large-scale studies demonstrating that laparoscopic D2 dissection, the standard lymphadenectomy for AGC, is equivalent to open surgery. Recently, some studies have evaluated the outcome of D2 lymph node dissection in LAG and open surgery for gastric cancer.¹⁶⁻¹⁹ In this study, we evaluated operative blood loss, operative time, blood transfusion, morbidity, mortality, the number of harvested lymph nodes (HLNs) with emphasis on HLNs between LAG and OG.

MATERIALS AND METHODS

Retrospective data was collected from 36 patients who underwent total gastrectomy for carcinoma stomach over a period of 4 years from March 2009 to June 2012 in the Department of Surgery SCB Medical College, Cuttack, India. The exclusion criteria included: (1) invasion of adjacent structures; (2) distant metastases; and (3) associated comorbid conditions making unfit to undergo surgery. Routine blood examination, chest X-ray, contrast-enhanced computed tomographic scan of the abdomen and pelvis and endoscopy were performed before operation. Biopsy revealed adenocarcinoma in all cases. The study population thus included 20 cases that successfully underwent radical gastrectomy with D2 dissection. Twenty-one cases underwent LAG and other 15 OG. Mean period of follow-up was 8 months.

OPERATIVE PROCEDURE

Laparoscopy-assisted total gastrectomy with D2 dissection: This procedure was performed for gastric cancer involving more than two-third of the stomach. Under five port approach (Fig. 1) the greater omentum was first dissected, using the harmonic scalpel along the border of the transverse colon. The right gastroepiploic vessel was clipped and cut at its origin with the harmonic; lymph nodes alongside of it were removed. The duodenal tunnel was made and duodenum was divided 2 cm distal to prepyloric vein using linear cutting stapler (Fig. 2). Then the left gastroepiploic vessel was cut, allowing lymph nodes alongside it to be removed. Then the gastropancreatic fold was exposed. Along with the gastroduodenal artery, the common hepatic artery could be skeletonized easily. The right gastric artery was divided and cut at its origin, from the proper hepatic artery to complete dissection of lymph nodes alongside of it. Then the lymph nodes located along the celiac trunk and the left gastric artery was removed. The left gastric artery was cut from the celiac trunk using clips. Then the splenic artery was skeletonized from its origin to the end in order to remove lymph nodes. After returning the stomach and the greater omentum to normal position, the lesser omentum could be resected close to the liver edge (Fig. 3) to the esophagogastric junction, with dissection of lymph nodes. Lastly lymph nodes along the hepatic artery were dissected. After standard D2 dissection was completed, an upper midline incision (about 10 cm) was made. The gastrectomy was performed using knife at the esophagogastric junction (Fig. 4) and esophagojejunostomy was done using circular stapler (Figs 5 and 6) (Ethicon make) and jejunojunctionostomy was done to complete Roux-en-y anastomosis.

In open gastrectomy (OG) upper midline incision about 20 cm was given and the procedure is same as LAG.

Postoperatively patients were on Ryle's tube for minimum of 5 days. Oral liquids were started from 6th postoperative day. During surgery, operative time, blood loss, and the amount of blood transfusion were recorded. Postoperative complications, categorized as surgical and nonsurgical complications were observed. Mortality was defined as any death that occurred during hospital stay. The depth of tumor invasion, tumor size, margins, the number of HLN's, and positive lymph nodes were determined by pathological analysis.

RESULTS

There were no significant differences in morbidity or mortality in both groups. Tumor free margins were obtained in all cases. Compared with OG group, the LAG group had

significantly less blood loss, but a longer operation time. Since, we were interested in the number of lymph node harvested, the mean HLN's were 24.7 in LAG group as compared 23.3 in OG group.




Fig. 1: Port positions in laparoscopic gastrectomy



Fig. 2: Division of pylorus distal to prepyloric vein using linear cutter stapler




Fig. 3: Division of lesser omentum close to liver edge



Fig. 4: Gastrectomy performed using knife at the esophago-gastric junction



Fig. 5: Anvil placed into the esophagus



Fig. 6: Docking of anvil into circular stapler

DISCUSSION

For the treatment of AGC, surgical procedures include gastrectomy and lymphadenectomy. However, the extent of lymph node dissection has remained controversial

worldwide.¹⁹ In Eastern Asian countries such as Japan, China, and Korea, D2 dissection has been the standard operation.²⁰ However, in Western countries, D2 dissection is thought to be accompanied by significant mortality and morbidity, with no survival advantage.²¹⁻²³ Hartgrink et al²² reported the results of a Dutch gastric cancer group trial in 2004, which included 711 patients who underwent randomly assigned treatment with curative intent (380 in D1 and 331 in D2). Both the postoperative morbidity (25 vs 43%, $p < 0.001$) and mortality (4 vs 10%, $p = 0.004$) were significantly higher in patients who underwent D2 dissection, while there was no difference in the 11-year overall survival (30 vs 35%, $p = 0.53$) between the two groups. Those results were similar to that of the Medical Research Council Gastric Cancer Surgical Trial.²² However, the conclusions drawn from those two famous RCTs were questioned by Eastern investigators. The main concern was that 80 centers participated in the Dutch gastric cancer group trial, so the mean number of patients who underwent D2 dissection in each center was less than 5. Thus, the discomenders considered it very difficult to perform safe and standard D2 dissections in each center. Unexpectedly, in the 15-year follow-up from the Dutch gastric cancer group trial, published in 2010,²⁴ the gastric cancer-related death rate of the D2 group was significantly lower than that of the D1 group (37 vs 48%, $p = 0.01$), local recurrence was 12% in the D2 group vs 22% in D1, and regional recurrence was 13% in D2 vs 19% in D1. Thus, the authors recommended D2 dissection as the standard surgical approach for resectable gastric cancer. Currently, more and more evidences have proved D2 dissection as a feasible and safe procedure with survival advantages as compared with the D1 dissection,²⁵⁻²⁷ and D2 dissection has been gradually accepted by Western investigators. In the 2010 National Comprehensive Cancer Network guidelines, the panel recommended that gastric cancer surgery should remove D2 lymph nodes with the goal of examining 15 or more lymph nodes. Although, D2 dissection is performed in AGC as a standard procedure, more and more investigators have emphasized the need for D2 dissection in EGC because of preoperative understaging.^{28,29} In gastric cancer, laparoscopic surgery has not yet been validated, and thus, was only performed in a limited number of patients with EGC in six small-scale RCTs;^{10-13,15} this was due to the difficulties in systematic lymph node dissection, especially in the standard D2 dissection. The number of HLNs is regarded as an important short-term oncological outcome of laparoscopic D2 dissection. Several recent retrospective studies have shown that laparoscopic D2 dissection is both a safe and oncologically feasible procedure, with a similar number of HLNs compared with open dissection.^{16-19,28} Du

et al¹⁶ evaluated 82 patients with AGC who underwent laparoscopy-assisted total gastrectomy with D2 dissection compared with 94 patients who received open surgery; a similar number of HLNs was obtained in both groups (34.2 ± 13.5 vs 36.4 ± 19.1 , $p = 0.331$). In our hospital we are doing D2 dissection for all cases of gastric cancer. In this study we want to highlight that laparoscopic D2 gastrectomy provides same result as that of open surgery even in terms of HCNs as there is very much debate now over this issue which is also an important prognostic factor.

CONCLUSION

Laparoscopic dissection and harvested lymph nodes is equivalent to OG with no other significant differences except for decreased blood loss and increased operative time. Thus, this procedure can achieve the same result as OG. However, large-scale RCTs with a longer follow-up period should be carried out in future studies to prove that LAG with D2 dissection is a good alternative to OG in selected patients.

REFERENCES

- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006 May;24(14):2137-2150.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. *Int J Cancer* 2010 Dec;127(12):2893-3917.
- Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. *Cancer Epidemiol Biomarkers Prev* 2005;14:243-250.
- Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. *Gastric Cancer* 2002;5:177-182.
- Kiyama T, Mizutani T, Okuda T, Fujita I, Yamashita N, Ikeda K, et al. Laparoscopic surgery for gastric cancer: 5 years' experience. *J Nihon Med Sch* 2006 Aug;73(4):214-220.
- Goh P, Tekant Y, Isaac J, Kum CK, Ngoi SS. The technique of laparoscopic Billroth II gastrectomy. *Surg Laparosc Endosc* 1992 Sep;2(3):258-260.
- Tanimura S, Higashino M, Fukunaga Y, Kishida S, Ogata A, Fujiwara Y, Osugi H. Laparoscopic gastrectomy with regional lymph node dissection for upper gastric cancer. *Br J Surg* 2007 Feb;94(2):204-207.
- Jeong GA, Cho GS, Kim HH, Lee HJ, Ryu SW, Song KY. Laparoscopy-assisted total gastrectomy for gastric cancer: a multicenter retrospective analysis. *Surgery* 2009 Sep;146(3):469-474.
- Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. *J Am Coll Surg* 2010 Jul;211(1):33-40.
- Fujii K, Sonoda K, Izumi K, Shiraishi N, Adachi Y, Kitano S. T-lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. *Surg Endosc* 2003 Sep;17(9):1440-1444.
- Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. *Surgery* 2002 Jan;131(1 Suppl):S306-S311.
- Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. *Surg Endosc* 2005 Feb;19(2):168-173.
- Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. *Surg Endosc* 2005 Sep;19(9):1172-1176.
- Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, Ponzano C. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005 Feb;241(2):232-237.
- Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, Bae JM. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. *Ann Surg* 2008 Nov;248(5):721-727.
- Du J, Zheng J, Li Y, Li J, Ji G, Dong G, Yang Z, Wang W, Gao Z. Laparoscopy-assisted total gastrectomy with extended lymph node resection for advanced gastric cancer-reports of 82 cases. *Hepatogastroenterology* 2010 Nov;57(104):1589-1594.
- Huang JL, Wei HB, Zheng ZH, Wei B, Chen TF, Huang Y, Guo WP, Hu B. Laparoscopy-assisted D2 radical distal gastrectomy for advanced gastric cancer. *Dig Surg* 2010;27(4):291-296.
- Lee JH, Kim YW, Ryu KW, Lee JR, Kim CG, Choi IJ, Kook MC, Nam BH, Bae JM. A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. *Ann Surg Oncol* 2007 Nov;14(11):3148-3153.
- Obama K, Okabe H, Hosogi H, Tanaka E, Itami A, Sakai Y. Feasibility of laparoscopic gastrectomy with radical lymph node dissection for gastric cancer: from a viewpoint of pancreas related complications. *Surgery* 2011 Jan;149(1):15-21.
- Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? *Crit Rev Oncol Hematol* 2001 Oct;40(1):77-94.
- Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. *Surgical Cooperative Group. Br J Cancer* 1999 Mar;79(9-10):1522-1530.
- Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004 Jun;22(11):2069-2077.
- Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010 May;11(5):439-449.
- Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. *Eur J Surg Oncol* 2004 Apr;30(3):303-308.

25. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. *Br J Cancer* 2004 May;90(9):1727-1732.
26. Sierra A, Regueira FM, Hernández-Lizoáin JL, Pardo F, Martínez-Gonzalez MA, A-Cienfuegos J. Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. *Ann Surg Oncol* 2003 Apr;10(3):219-226.
27. Huscher CG, Mingoli A, Sgarzini G, Brachini G, Binda B, Di Paola M, Ponzano C. Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early and advanced gastric cancer: early and long-term results of a 100-patient series. *Am J Surg* 2007 Dec;194(6):839-844; discussion 844.
28. Pugliese R, Maggioni D, Sansonna F, Scandroglia I, Ferrari GC, Di Lernia S, Costanzi A, Pauna J, de Martini P. Total and subtotal laparoscopic gastrectomy for adenocarcinoma. *Surg Endosc* 2007 Jan;21(1):21-27.
29. Pugliese R, Maggioni D, Sansonna F, Ferrari GC, Forgiione A, Costanzi A, Magistro C, Pauna J, Di Lernia S, Citterio D, et al. Outcomes and survival after laparoscopic gastrectomy for adenocarcinoma. Analysis on 65 patients operated on by conventional or robot-assisted minimal access procedures. *Eur J Surg Oncol* 2009 Mar;35(3):281-288.

ABOUT THE AUTHORS

T Anil Kumar

Postgraduate Student, Department of Surgery, SCB Medical College Cuttack, Odisha, India

Manoj Gowda

Postgraduate Student, Department of Surgery, SCB Medical College Odisha, India

Manash Ranjan Sahoo (Corresponding Author)

Associate Professor, Department of Surgery, SCB Medical College Cuttack, Odisha, India, e-mail: manash67@gmail.com